Latest News and Press Releases

Cystic Fibrosis Foundation Approves Letter of Application Enabling Protalix to Apply for Grant Funding Debt Refinancing and Financing Significantly improves Financial Position CARMIEL, Israel, Aug. ...

CARMIEL, Israel, July 31, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...

CARMIEL, Israel, July 25, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) (“Protalix” or the “Company”) announced today the entry into a definitive exchange...

New clinical data reported on ppFEV1 measurement taken after washout of alidornase alfa demonstrates meaningful decrease in efficacy parameters once treatment with alidornase alfa stopped further...

CARMIEL, Israel, June 01, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that a Supplemental New Drug Application (sNDA) submitted to the U.S....

CARMIEL, Israel, May 25, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...

CARMIEL, Israel, May 23, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX), announced today that an oral presentation highlighting the results from the...

Positive Results from Phase II Trial in CF Program with Number of Potential Strategic Alternatives for Further Development First Ever Once Monthly Dosing Trial in Fabry Patients to Commence Next...

Once Monthly Dosing Would Represent a 50% Reduction in Patient Infusions Unique Chemical Modifications to pegunigalsidase alfa Result in a Significantly Longer Half-life Allowing for the Potential of...

CARMIEL, Israel, May 01, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...